RxDoctor Payments Data

Erick Huarcaya, MD

Family Medicine · Phoenix, AZNPI 1245379288

Payments from drug & device makers

$6,411in general payments, 2019–2025

Across 312 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$691
  • Novo Nordisk$606
  • Daiichi Sankyo Inc.$445
  • Bayer$409
  • Lilly USA, LLC$399
  • Boehringer Ingelheim$255
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$6,410100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,411 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$22,177
Medicare patients
73
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol160$155,964
JardianceEmpagliflozin104$98,418
OzempicSemaglutide54$57,829
TrulicityDulaglutide35$53,839
KerendiaFinerenone60$47,830
RybelsusSemaglutide31$44,788
MounjaroTirzepatide36$41,734
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$32,949
TradjentaLinagliptin23$24,740
LinzessLinaclotide24$24,632
GemtesaVibegron28$23,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,086
JanuviaSitagliptin Phosphate19$19,588
GlyxambiEmpagliflozin/Linagliptin14$18,136
EliquisApixaban16$17,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$184$188,912203 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$255$141,293141 claims
Novo NordiskOzempic, Rybelsus$606$102,61785 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$399$97,02583 claims
BayerKerendia$409$47,83060 claims
AbbVieLinzess$200$24,63224 claims
Sumitomo Pharma America, Inc.Gemtesa$26$23,22028 claims
GSKTrelegy Ellipta$97$22,08627 claims
PfizerEliquis$160$17,45516 claims
Sanofi-aventis U.S. LLCLantus$82$3,03124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →